We studied interleukin-6 (IL-6) levels on the day of transplantation in 31 patients undergoing autologous haemopoietic stem cell transplantation (SCT) (either peripheral blood stem cell transplantation (PBSCT) or bone marrow transplantation (BMT)) for neoplastic diseases to determine if there was a relationship between IL-6 level and rate of haemopoietic recovery, length of stay in hospital, and survival. There was no apparent delay in post-transplant recovery associated with elevated IL-6 levels. However, increased values of IL-6 tended to be associated with an increased length of stay in hospital (P = 0.083). There was a highly significant adverse association between higher IL-6 levels and survival following transplantation (P = 0.0001). This association remained significant (P = 0.013) in the uniform subgroup of patients with malignant lymphoma with chemosensitive disease who had undergone BMT (that is, excluding patients who had undergone PBSCT) (n = 13). Knowledge of IL-6 levels on the day of transplant has the potential to provide valuable prognostic information in patients undergoing autologous haemopoietic SCT. Bone Marrow Transplantation (2001) 28, 929-933.
including the immunological response, 3 inflammatory process, 4 bone metabolism 5 and thrombopoiesis. 6 It may be increased in infections 7 and in patients with Hodgkin's disease (HD). 8 High serum levels correlate with adverse features and poor survival in patients with newly diagnosed low-grade non-Hodgkin's lymphoma (NHL). 9, 10 We hypothesized that levels of IL-6 measured on the day of transplantation might be an indicator of haemopoietic recovery and survival.
Patients and methods
From November 1994 to September 1998, IL-6 was measured on the day of transplantation (day 0) in 31 patients who underwent autologous SCT for malignant disorders. In 10 cases, stem cells had been collected from the peripheral blood (PBSC): either after G-CSF priming alone (10 g/kg per day for 6 days; n = 6), or after administration of cyclophosphamide 2-5 g/m 2 daily for 4 days followed by G-CSF (n = 3), or after vincristine, doxorubicin and dexamethasone followed by G-CSF (n = 1). In the remaining 21 cases the stem cells had been obtained from the bone marrow (BM), either from resting BM (n = 10) or from BM after G-CSF priming (n = 11).
11 Table 1 shows patients grouped by stem cell source and ranked by IL-6 level on the day of transplant; diagnoses and other patient characteristics are also shown. The most common diagnosis was malignant lymphoma, including NHL (n = 14) and HD (n = 5). Pre-transplant myeloablative therapy for lymphoma patients was with BEAM; 12 multiple myeloma patients received busulfan and melphalan, and a variety of protocols was used for other diagnoses. Only one patient had a fully documented complete remission at the time of transplant (UTN 51, Table 1 ); all others had evidence of persisting or residual disease. On the other hand, only five patients had disease that was resistant to chemotherapy at the time of transplantation. All patients were afebrile and none was clinically infected on day 0. Following transplantation patients were given subcutaneous G-CSF 5 g/kg daily until neutrophil recovery. Prophylactic antibiotics were not given routinely.
With regard to the number of days in hospital, our unit has a policy of early discharge after transplantation. Patients may be discharged prior to cell recovery if they are clinically stable, eating satisfactorily and able to attend daily for review. Prolongation of hospital stay is usually determined by ongoing active infection and/or complications of severe mucositis, such as diarrhoea. The clinicians who determined the day of discharge had no knowledge of IL-6 levels.
The total IL-6 (receptor-bound plus free) was measured using the Medgenix IL-6 EASIA kit from BioSource Europe SA (Fleurus, Belgium), according to the manufacturer's instructions. Serum was separated on the day of transplant, frozen at −80°C, and thawed for measurement in batches. The IL-6 concentration is normally low (Ͻ10 pg/ml) or undetectable, 13 but it was detected in all 31 patients in this study (range 3-500 pg/ml). So as not to introduce post hoc bias, we dichotomised patients for the purpose of analysis according to the manufacturer's definition of the upper limit of normal for IL-6, namely 10 pg/ml. If, instead, we had selected the median (16 pg/ml) as the dividing point, the adverse effect of high IL-6 levels on survival would have been demonstrated even more starkly (data not shown).
Recovery times of neutrophils to 0.5 × 10 9 /l, total white cell count (WCC) to 1.0 × 10 9 /l and platelets (unsupported) to 20 and 50 × 10 9 /l were obtained from records kept in the bone marrow transplant database. Recovery times were censored on date of death if patients died before recovery. Length of stay in hospital was calculated as the total number of nights that the patient was an inpatient (admitted to hospital) during the first 30 days post transplant, and was censored on the date of death if patients died before discharge.
Statistics
This was a retrospective exploratory analysis. The followup period for each patient was determined from the date of his or her transplant to the study close-out date of 31 May 1999 . The status of all patients was known on this date. IL-6 was analysed both as a dichotomous and as a continuous variable. Comparisons of IL-6 levels in males and females and patients with and without lymphoma were made using the Wilcoxon-Mann-Whitney test. Association of IL-6 with age was tested using the Spearman rank correlation coefficient. Length of stay in hospital, haematological recovery times and overall survival were analysed using the Cox proportional hazards regression model. The significance of an individual factor in a given model was determined by the change in the likelihood value if that factor was removed from the model. Two-sided significance levels have been reported throughout, with no adjustment for multiple comparisons. Hazard ratios (HR) representing relative death rates have been reported along with their 95% confidence intervals (CI). Survival estimates were obtained using the Kaplan-Meier (product-limit) method. Statistical analyses were carried out using SPSS 14, 15 and StatXact 16 software.
Results

IL-6
The distribution of IL-6 levels on the day of transplantation was highly skewed, with a median of 16 pg/ml, mean 49.5 pg/ml and range of 3-500 pg/ml. IL-6 was elevated (у10 pg/ml) in 21 (68%) of the 31 patients studied. The IL-6 levels were significantly higher in females than in males (P = 0.0052), being elevated in 12 (80%) of the 15 females and nine (56%) of the 16 males (median 48 vs 10.5 pg/ml). There was no apparent association with age or diagnosis.
Survival
When all 31 patients were analysed, those with elevated IL-6 levels had a significantly shorter survival duration than those with lower values (estimated HR 5.5, P = 0.046) on unifactor analysis (Table 2, Figure 1 ). Since treating IL-6 as a dichotomous variable (high values or low values) potentially throws away the possible predictive power in the individual values, models using the actual IL-6 values and models using log 10 (IL-6) were tested. Log 10 (IL-6) was more strongly associated with survival duration (P = 0.0001) than the actual IL-6 values (P = 0.0009). Log 10 (IL-6) was associated with an estimated HR of 9.4 (Table 2 ). Female patients also had a significantly shorter survival than males (P = 0.0002). As it was possible that this was due to the female patients having higher IL-6 values than Overall survival according to IL-6 levels of all patients studied, indicating that elevated IL-6 levels are associated with decreased survival duration (P = 0.046).
male patients, the joint significance of IL-6 and sex were studied in a regression model. Both sex and IL-6 were statistically significant (P = 0.020 and P = 0.048, respectively). There was no evidence of any interaction between these two factors (P = 0.77).
The total study population was heterogeneous with respect to diagnoses and other characteristics. In particular, it included six patients with gender-specific cancers and five patients who were known to have resistant disease (Table 1) . Accordingly, we also analysed a uniform subgroup of patients with a diagnosis of lymphoma (HD or NHL) who had undergone a BMT (that is, excluding those who underwent PBSCT) and who had chemosensitive disease (n = 13). Within this subgroup, IL-6 was still significantly associated with survival (P = 0.013; Table 2 ). Although females tended to have a shorter survival than males, the difference was not significant on univariate analysis (P = 0.22) and there was no evidence of an association on multivariate analysis adjusting for IL-6 (estimated HR = 0.94, P = 0.94). However, because of the small number of patients studied, the confidence intervals for all the hazard ratios are wide.
Of the 31 patients in the study, only three died before day 30. All three were NHL patients with high IL-6 levels who underwent a BMT. Two of the three deaths were due to multi-organ failure and the other to overwhelming sepsis.
Haematological recovery
When patients as a whole were compared, there was no difference in haematological recovery time between the two IL-6 groups.
Hospital stay
Patients with higher IL-6 levels tended to have longer lengths of stay in hospital during the 30-day post-transplant period, but the difference was not statistically significant (P = 0.083).
Discussion
The known functions of IL-6 include the induction of acute phase proteins and thrombopoiesis. 6 The effect of cytokines other than haemopoietic growth factors on SCT is poorly understood and there is only limited information about IL-6 and autologous transplantation in the literature. [17] [18] [19] [20] [21] However, in the allogeneic setting, a difference has been shown in the levels of IL-6 between those with a complicated posttransplantation course and those without complications. 22 IL-6 levels are normally low or undetectable, but chemotherapy-induced myeloablation can bring about a rise in the IL-6 concentration in the blood above baseline. 23 All patients in this study had detectable IL-6 following their myeloablative chemotherapy, but results varied from normal to grossly elevated (3-500 pg/ml). Analysing IL-6 as a dichotomous variable showed the clear adverse effect on survival of having high levels (P = 0.046), but the effect was even more strikingly demonstrated when IL-6 levels were analysed as a continuous variable, particularly taking log 10 (IL-6) values (P = 0.0001). Log 10 (IL-6) was associated with an estimated HR of 9.4; thus, for every 10-fold increase in the IL-6 values, there was an estimated 9.4-fold increase in the rate of death.
This retrospective case study has identified a significant relationship between IL-6 level on the day of transplantation with overall survival, when all patients were analysed together. Because the patients were heterogeneous, we also studied a homogeneous subgroup, namely lymphoma patients undergoing BMT (not PBSCT) who had chemosensitive disease and who had all received BEAM as their myeloablative treatment. 12 The adverse relationship between IL-6 levels and survival was maintained in this subgroup.
As has been reported previously by others, we found no statistically significant relationship between IL-6 levels and rate of haematological recovery following SCT. 17, 24 An unexpected finding was a disproportionate gender distribution of IL-6 levels. When survival was analysed according to gender, it was found that male patients had a significantly increased survival compared to female patients (P Ͻ 0.0001). However, the female cases included patients with advanced breast cancer and advanced ovarian cancer, diagnoses that would be expected to have a poor prognosis after transplantation. In the homogeneous subgroup of lymphoma patients with chemosensitive disease who underwent BMT after BEAM conditioning, it was found that there was no significant difference between male and female survival (P = 0.22). Despite this, it is of interest to note that others have also found female sex to be an adverse prognostic factor following autologous transplantation. 25 The explanation for the significant relationship between high IL-6 levels and reduced survival is unclear. Although IL-6 levels are elevated in patients with inflammatory disorders including sepsis, 7 all of our patients were free of clinical sepsis on day 0 when the sample for IL-6 analysis was taken, and only three died within 30 days of the transplant. The relationship we found was, in fact, between IL-6 levels on day 0 and overall survival, including survival beyond the immediate transplant period. The great majority of the eventual deaths were disease-related. It is possible that IL-6 levels on the day of transplant reflected underlying bulk or extent of disease, or chemotherapy-induced tumour lysis, although this was not clinically apparent. Others have reported that prognosis after SCT is significantly worse in patients with bulky disease at the time of transplantation compared with those with minimal disease, [26] [27] [28] although not all authors agree. 29 It is unlikely that IL-6 itself is responsible for the adverse outcomes, given that IL-6 has been administered in a therapeutic trial to patients after autologous BMT without apparent adverse effects. 30 Another possible explanation for the remarkable variation we found in IL-6 levels, and their association with outcome, may lie in genetic variability. Marked differences are seen in the cytokine response to stimuli between individuals and some of these have been shown to correlate with genetic polymorphisms. These differences may also correlate with disease susceptibility or outcome. For example, genetic polymorphisms in the IL-6 gene locus have been associated with a reduced incidence of Still's disease and also variations in bone mineral density and risk of development of osteoporosis. 31 Such polymorphisms in the IL-6 gene have not yet been shown to be associated with outcomes from BMT, but polymorphism genotypes for a related cytokine, TNF alpha, may influence outcome after allogeneic BMT by affecting severity of graft-versushost disease. 32 Since TNF alpha is a potent stimulant for the production of IL-6, it is tempting to speculate that our results might have the same cause. If this is so, perhaps measurement of the IL-6 response to a stimulus prior to BMT might be an indicator of prognosis following the procedure.
Prospective research is needed to measure IL-6 levels prior to commencement of, as well as during ablative therapy, rather than just on the day of transplant. If the adverse outcomes of patients with high IL-6 levels can be confirmed, IL-6 measurement may form a valuable prognostic marker in the assessment of patients for haemopoietic stem cell transplantation. allowing us to study their patients. This work was partially supported by grants from the Cancer Council of Tasmania and the David Collins Leukaemia Foundation.
